Radotinib (INN; trade name Supect) is a drug for the treatment of some types of cancer. It is approved in Korea for use as a second-line treatment of chronic myeloid leukemia (CML). Its mechanism of action involves inhibition of the tyrosine kinase Bcr-Abl and of platelet-derived growth factor receptor (PDGFR).
This page contains content from the copyrighted Wikipedia article "Radotinib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
